This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción NTR
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Spectrum Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$1.55 |
| 52 Week Low | US$0.26 |
| Beta | 2.14 |
| 1 Month Change | 4.28% |
| 3 Month Change | -1.28% |
| 1 Year Change | 11.63% |
| 3 Year Change | -66.96% |
| 5 Year Change | -94.93% |
| Change since IPO | -67.54% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| NTR | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0.5% | -0.2% | 0.5% |
| 1Y | 11.6% | -22.8% | 1.3% |
Rentabilidad vs. Industria: NTR exceeded the German Biotechs industry which returned -7.1% over the past year.
Rentabilidad vs. Mercado: NTR exceeded the German Market which returned 6.7% over the past year.
Volatilidad de los precios
| NTR volatility | |
|---|---|
| NTR Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: NTR's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: NTR's weekly volatility has decreased from 18% to 8% over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1987 | 86 | Tom Riga | www.sppirx.com |
Resumen de fundamentos de Spectrum Pharmaceuticals, Inc.
| Estadísticas fundamentales de NTR | |
|---|---|
| Capitalización bursátil | €191.11m |
| Beneficios(TTM) | -€61.65m |
| Ingresos (TTM) | €23.43m |
8.2x
Ratio precio-ventas (PS)-3.1x
Ratio precio-beneficio (PE)¿Está NTR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NTR | |
|---|---|
| Ingresos | US$25.73m |
| Coste de los ingresos | US$2.86m |
| Beneficio bruto | US$22.87m |
| Otros gastos | US$90.58m |
| Beneficios | -US$67.71m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.33 |
| Margen bruto | 88.90% |
| Margen de beneficio neto | -263.16% |
| Ratio deuda/patrimonio | 107.6% |
¿Cómo se ha desempeñado NTR a largo plazo?
Ver rendimiento histórico y comparativa